SMMT on Nasdaq

Summit Therapeutics

Biopharmaceutical company.1

Price unavailable

Last updated Oct 19, 2026.

Overview

2003Founded1

Compare with Lexaria Bioscience Corp., Unicycive Therapeutics, Inc. or Karuna Therapeutics, or pick any stock.

  • TickerSMMT on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersMenlo Park1
  • Websitewww.summittxinc.com
  • Business address601 Brickell Key Drive, Suite 1000, Miami, Fl 331313
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Summit Therapeutics Inc. (“we”, “Summit” or the “Company”) is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company’s pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-56.9%Return on equity5
-$142.2MFree cash flow5

Financial statements

Revenue6789$0 in 2024
0$20.0M$40.0M$60.0M2019: $57.1M$57.1M20192020: $860.0K$860.0K2020−98%2021: $1.8M$1.8M2021+110%2022: $705.0K$705.0K2022−61%2023: $0$020232024: $0$02024
Operating income6789-$226.0M in 2024
-$800.0M-$600.0M-$400.0M-$200.0M0$200.0M2019: $5.4M$5.4M20192020: -$53.2M-$53.2M20202021: -$86.2M-$86.2M2021+62%2022: -$72.1M-$72.1M2022−16%2023: -$609.6M-$609.6M2023+746%2024: -$226.0M-$226.0M2024−63%
Net income67895-$221.3M in 2024
-$800.0M-$600.0M-$400.0M-$200.0M0$200.0M2019: $10.9M$10.9M20192020: -$52.7M-$52.7M20202021: -$88.6M-$88.6M2021+68%2022: -$78.8M-$78.8M2022−11%2023: -$614.9M-$614.9M2023+681%2024: -$221.3M-$221.3M2024−64%
Fiscal year201920202021202220232024
Revenue$57.1M6$860.0K7$1.8M8$705.0K9$09$09
Gross profit2.7M GBP10
Research and development$52.0M6$53.3M7$85.4M8$52.0M13$59.5M13
Operating expenses$109.0M8$87.2M9$609.6M5$226.0M5
Operating income$5.4M6-$53.2M7-$86.2M8-$72.1M9-$609.6M9-$226.0M9
Interest$620.0K6$255.0K7$242.0K8$4.4M8
Income before tax-$88.6M8-$78.8M9-$614.9M5-$221.3M5
Income tax-$1.8M6-$213.0K7$07$05$05
Net income$10.9M6-$52.7M7-$88.6M8-$78.8M9-$614.9M5-$221.3M5
Earnings per share$0.636-$0.767-$0.678-$0.419-$0.995-$0.315
Earnings per share (diluted)$0.636-$0.767-$0.678-$0.419-$0.995-$0.315
Shares (weighted, basic)131.7M shares8193.3M shares9619.6M shares5718.5M shares5
Shares (weighted, diluted)131.7M shares8193.3M shares9619.6M shares5718.5M shares5

Compare Summit Therapeutics with another company

Leadership

Who has led Summit Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Robert W. Duggan2020–2022
  2. Maky Zanganeh2022–now

President

  1. Maky Zanganeh2022–2023

Chief financial officer

  1. Ankur Dhingra2022–2024
  2. Manmeet Singh Soni2024–now

Chief operating officer

  1. Maky Zanganeh2020–2021
  2. Manmeet Singh Soni2023–now
20052010201520202025
Board members and other officers (19)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorMahkam Zanganeh named Jun 18, 2024 to Sep 26, 202437
  • DirectorKenneth Clark named Jun 18, 2024 to Sep 26, 202437
  • DirectorMostafa Ronaghi named Jun 18, 2024 to Sep 26, 202437

Former names

  • Summit Therapeutics plcDec 31, 2014 to Sep 17, 20203
  • Summit Corp plcMar 4, 2014 to Jan 30, 20153

Timeline

  1. Aug 18, 2022New chief executive Maky Zanganeh becomes CEO14
  2. Oct 6, 2020New chief executive Robert W. Duggan becomes CEO15
  3. Mar 5, 2015Went public Listed on NASDAQ1
  4. 2003Founded Founded1

Filings

287 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 102 major events, 104 insider forms, 7 large holders, 2 private raises, 51 other. The latest 20:

  1. Oct 14, 20264 EDGAR
  2. Oct 6, 2026PRE 14A EDGAR
  3. Sep 29, 20268-K EDGAR
  4. Sep 15, 20268-K EDGAR
  5. Sep 14, 20268-K EDGAR
  6. Sep 3, 20268-K EDGAR
  7. Aug 26, 20268-K EDGAR
  8. Aug 5, 20268-K EDGAR
  9. Jul 23, 202610-Q EDGAR
  10. Jul 23, 20268-K EDGAR
  11. Jul 23, 20268-K EDGAR
  12. Jul 23, 2026424B5 EDGAR
  13. Jul 22, 20268-K EDGAR
  14. Jun 12, 20268-K EDGAR
  15. Jun 12, 20264 EDGAR
  16. Jun 12, 20264 EDGAR
  17. Jun 11, 20268-K EDGAR
  18. Jun 10, 2026424B5 EDGAR
  19. Jun 9, 2026S-3ASR EDGAR
  20. Jun 4, 20264 EDGAR

The 287 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

28 open-market trades by officers, directors and large owners since October 2021: 28 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 12, 2026Zanganeh MahkamCo-Chief Executive OfficerBuy3,810,000$13.12$50.0MForm 4
Jun 12, 2026DUGGAN ROBERT WCo-Chief Executive OfficerBuy3,810,000$13.12$50.0MForm 4
Jun 4, 2026Soni Manmeet SinghCOO and CFOBuy50,000$14.45$722.2KForm 4
Jun 4, 2026Zanganeh MahkamCo-Chief Executive OfficerBuy100,000$14.60$1.5MForm 4
Jun 4, 2026DUGGAN ROBERT WCo-Chief Executive OfficerBuy100,000$14.60$1.5MForm 4
Oct 21, 2025Xia YuDirectorBuy533,617$18.74$10.0MForm 4
Oct 21, 2025Zanganeh MahkamCo-Chief Executive OfficerBuy26,680$18.74$500.0KForm 4
Oct 21, 2025DUGGAN ROBERT WCo-Chief Executive OfficerBuy26,680$18.74$500.0KForm 4
Sep 11, 2025Zanganeh MahkamCo-Chief Executive OfficerBuy5,000$18.07$90.3KForm 4
Sep 11, 2025DUGGAN ROBERT WCo-Chief Executive OfficerBuy5,000$18.07$90.3KForm 4
Sep 10, 2025Zanganeh MahkamCo-Chief Executive OfficerBuy333,394$17.68$5.9MForm 4
Sep 10, 2025DUGGAN ROBERT WCo-Chief Executive OfficerBuy333,394$17.68$5.9MForm 4
Mar 27, 2024Zanganeh MahkamCo-Chief Executive OfficerBuy80,321$3.72$298.6KForm 4
Mar 26, 2024Zanganeh MahkamCo-Chief Executive OfficerBuy30,000$3.75$112.5KForm 4
Mar 26, 2024Dhingra AnkurChief Financial OfficerBuy100,000$3.75$375.0KForm 4
Dec 13, 2023Dhingra AnkurChief Financial OfficerBuy20,400$2.17$44.3KForm 4
Dec 12, 2023Zanganeh MahkamCo-Chief Executive OfficerBuy5,000$2.07$10.3KForm 4
Oct 13, 2023Soni Manmeet SinghCOO and CFOBuy2,976,190$1.68$5.0MForm 4
Mar 8, 2023Zanganeh MahkamCo-Chief Executive OfficerBuy23,527,044$1.05$24.7MForm 4
Mar 8, 2023Zanganeh MahkamCo-Chief Executive OfficerBuy23,527,044$1.05$24.7MForm 4

All 28 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 11, 2024Raised $235 million in a private offering of equity Form D: 17 investors so far Form D
  2. Jun 3, 2024Raised $200 million in a private offering of equity Form D: 2 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40